The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Journal club

Journal club: how we handle discontinuation in obesity trials

Solved Closed
Solved by customs_ledger in post #2
I read the opening post twice before replying, because I had assumed the opposite. Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.

Jump to the accepted answer →

LS
l.solbergTL2 Moderator30 Jun 2025#1

On the subject in the title: Journal club: how we handle discontinuation in obesity trials Working notes rather than a conclusion.

Session topic: PIONEER 6 (N Engl J Med, 2019). Please read it before posting; the discussion is much better when everyone has.

The question I would like us to start with is what the trial set out to estimate, rather than what it found. Once that is on the table we can talk about whether the design could have answered it, and only then about the numbers.

Specific things I would like covered: the population and how far it generalises, how discontinuation was handled, whether the comparator was a fair one, and what the absolute rather than relative effect looks like.

I will summarise at the end and the summary will feed the relevant digest page.

15 likes 13mo
CL
customs_ledgerTL3Regular Solution19 Jul 2025#2

I read the opening post twice before replying, because I had assumed the opposite.

Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent.

19 likes 12mo
PM
p.mwangiTL2 Moderator2 Aug 2025 · edited#3
customs_ledger, post #2: I read the opening post twice before replying, because I had assumed the opposite. Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then limitations. That order makes critique coherent. Go to post

Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that question? (3) Was the population sufficiently similar to your population to apply the results? (4) What was the absolute effect, not just the relative one? (5) What are the two strongest criticisms available?

0 likes in reply to #2 12mo
This topic was closed 60 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

TopicParticipantsRepliesViewsActivity
Journal club: SURPASS-2 and the semaglutide 1 mg comparator
On the subject in the title: Journal club: SURPASS-2 and the semaglutide 1 mg comparator Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before posting;…
CRGBQLANFR+71 76 52k 21mo
Revisiting: Journal club: SURMOUNT-1, read without the press release
On the subject in the title: Revisiting: Journal club: SURMOUNT-1, read without the press release Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
PPKFAALMDN+54 62 1.5k 26d
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold?
Journal club: semaglutide in MASH, and surrogate endpoints — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J Med ,…
BDBEMVD 3 28k 6mo
Journal club: SURMOUNT-4 and continuation versus withdrawal
Journal club: SURMOUNT-4 and continuation versus withdrawal — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not…
ZNVDTTBMA+32 36 31k 3mo
[2026 update] Journal club: FLOW and the renal composite, component by component
Journal club: FLOW and the renal composite, component by component Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
NBTAC 2 21k 9d

Related topics — sharing the tags randomised trial, effect size, number needed to treat

TopicParticipantsRepliesViewsActivity
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP 4 (…
LSDOJFPWCL+6 10 13k 28d
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
LVBPNN 2 7.5k 2mo
Journal club: SURMOUNT-1, read without the press release
Journal club: SURMOUNT-1, read without the press release Writing it up because I had to work it out twice and would rather nobody else did. Session topic: STEP 1 ( N Engl J Med , 2021). Please read it before…
LKIRKSASP+139 157 66k 12mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
JBZOCRJATV+19 23 16k 2d